No matches
Type 2 Inflammation

EAACI 2024 | On-Treatment Clinical Remission in Upper and Lower Airways: ​ Going Beyond Symptom Control​

Join experts G. Walter Canonica, Vibeke Backer, and Joaquim Mullol for an educational symposium on elevating treatment goals from control to remission in the upper and lower airways.
G. Walter Canonica
Vibeke Backer
Joaquim Mullol
MD
G. Walter Canonica +2 more
Past event
31May2024
Location
Feria Valencia
Valencia Spain

Learning objectives

  • Recognize on-treatment clinical remission as a goal in patient care beyond symptom control in asthma and CRSwNP
  • Describe the evolving definition of on-treatment clinical remission in asthma as proposed in several consensus documents
  • Explore the emerging definition of remission in CRSwNP and its application to clinical practice

Description

Join the ADVENT program at the EAACI 2024 conference in Valencia, Spain for an educational symposium and expert panel discussion, on the emerging concept of remission in CRSwNP, the evolving picture of on-treatment clinical remission in asthma, and bringing elevated treatment goals into clinical practice.

Agenda

Welcome and Introductions

G. Walter Canonica (Chair)

Moving Beyond Control to On-Treatment Clinical Remission

G. Walter Canonica

Raising the Bar in Asthma Management: On-Treatment Clinical Remission 

Vibeke Backer

Overview of Asthma On-Treatment Clinical Remission Data

Vibeke Backer

Evolving Perspectives in CRSwNP Patient Care 

Joaquim Mullol

Panel Discussion

All Faculty

Q&A

All Faculty


This event is co-sponsored between EAACI 2024 and Sanofi and Regeneron. The speakers are being compensated and/or receiving honoraria from Sanofi and Regeneron in connection with this program.

Location

Feria Valencia
Valencia Spain
Tags
asthmaremission
MAT-GLB-2400421 - 2.0 - 03/2024

Speakers

Allergy/Immunology
MD

G. Walter Canonica

Head of Personalized Medicine Center, Asthma and Allergy | Humanitas Research Hospital, Milan, Italy

Pulmonology
DMSc, MD

Vibeke Backer

Chief Respiratory Physician, Department of ENT and Centre for Physical Activity Research | Rigshospitalet, Copenhagen, Denmark

Rhinology
MD, PhD

Joaquim Mullol

Director of the Rhinology Unit & Smell Clinic, Department of Otorhinolaryngology | Hospital Clinic, Barcelona, Spain; Professor of Research and Head of the Laboratory of Clinical and Experimental Respiratory Immunoallergy | August Pi i Sunyer Biomedical Research Institute, Barcelona, Spain | Head of Research Group at Biomedical Research Network on Respiratory Diseases (CIBERES) | Carlos III Institute of Health, Barcelona, Spain

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi | Regeneron Logo

© 2025 Sanofi and Regeneron Pharmaceuticals, Inc.

All rights reserved.
MAT-GLB-2302957 v3.0 11/2023

All Rights Reserved.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: South KoreaChange country/region